clinical trial · NCT04821687
A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD
SK Chemicals Co., Ltd.·phase4·completed·n = 169
Parkinson DiseaseOngentys 50mgMadopar Tab. 125 or Perkin Tab. 25-100mg
brief summary
A Study to evaluate the add-on efficacy and safety of opicapone 50 mg or an extra dose of L-DOPA 100 mg for the treatment of wearing-off in patients with PD.
started
Jun 17, 2021
primary completion
Aug 18, 2022
completion
Aug 18, 2022
last updated
Jun 1, 2023
official title
A Randomized, Parallel Group, Multicenter, Prospective, Open-label, Exploratory, Phase 4 Study to Evaluate the Add-on Effect of Opicapone 50 mg or Levodopa 100 mg as First Strategy for the Treatment of Wearing-off in Patients With Parkinson's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol